Investing in Travel and Tourism Stocks

Farmington, January 18, 2023 (GLOBE NEWSWIRE) — Global Market for mRNA vaccines and therapeutic agents was valued at US$707.97 million in 2022 and is projected to reach US$12.1 billion by 2030 at a CAGR of 1.7% between 2022 and 2030. An mRNA vaccine is a nucleic acid-based vaccine that contains messenger RNA and tells the patient’s cells to produce proteins as a treatment option. This vaccine can keep itself in check. mRNA vaccines use a mechanism within the host cell to convert mRNA into antigens that the immune system can recognize. When mRNA vaccines are used, there is no chance that the body will produce infectious particles. Messenger ribonucleic acid, or mRNA, is the only protein-coding gene in the genome that tells the cell how to make proteins. mRNA-based vaccines and RNAi-based therapeutics are made in the laboratory from mammalian cells and have good immunological properties.

Request a sample copy of the report “mRNA Vaccines & Therapeutics Market – Global Industry Analysis, Size, Share, Growth Opportunities, Future Trends, Impact of Covid-19, SWOT Analysis, Competition and Forecasts 2022-2030”, published by Contrive Datum Insights.

Recent improvements:

• July 2, 2021 Eurofins Agroscience Services (EAS) announced that Dr. Pete Cudi and Dr. Martin Cole are working with the EAS Hercules laboratory in North America to support the continued growth and development of our environmental hazard rating system and exercises.
• January 8, 2018 Argos Therapeutics Inc., an immuno-oncology company that develops and markets personalized immunotherapy based on the Arcelis® precision immunotherapy technology platform, announced today that it has signed an equity agreement with Lummy (Hong Kong), Ltd. (“Lummy”), a corporate partner of Rocapuldencel-T in China and other countries, has agreed to privately divest and sell 7.5 million shares of Lummy’s common stock (subject to any stock split, stock split, consolidation or combined events). the same cash extension relating to such shares), the total purchase price was $1.5 million. Trading in the shares is expected to end on or before March 7, 2018. Any ordinary shares of the company within 60 days from the closing date. The Company has agreed to file a registration statement with the Securities and Exchange Commission to register the resale of shares sold pursuant to a share purchase agreement.

Regional overview:

North America will account for over 5% of the market in 2021 and will grow the fastest during the forecast period. The North American market will be driven by the availability of big money for research, the growth of federal RNA drug discovery programs, and the growing number of clinical trials. For example, in November 2020, the National Institutes of Health (NIH), the Department of Defense (DoD), and federally funded academic laboratories helped Graham et al. with their basic research, which is an important part of the rapid development of a COVID-19 vaccine. Since the start of the pandemic, the government has given vaccine manufacturers an additional $10,500,000,000 to help them get their products to people faster.

Report Scope:

Report Attributes	Details
growth rate	average annual growth rate 1.7% from 2023 to 2030.
Revenue forecast for 2022	US$707.97 million
Type	Standardization of Cancer Treatment MRNA Vaccine, Individual Cancer Treatment MRNA Vaccine, Treatment of Infectious Diseases MRNA Vaccine, MRNA Vaccine to Prevent Infections, Other
By application	Hospital, Polyclinic, Other
By type of treatment	Monoclonal antibody, gene therapy, cell therapy, other
By companies	Argos Therapeutics, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, CRISPR Therapeutics, CureVac, eTheRNA immunotherapy, Ethris, GlaxoSmithKline Vaccines, In-Cell-Art, Intellia Therapeutics, Janssen, Kernal Biologics, MaxCyte, Moderna Therapeutics, Novartis, PhaseRx, Precision NanoSystems , RaNa Therapy
Regions and countries covered	North America: (USA, Canada, Mexico, rest of North America) Europe (Germany, France, Italy, Spain, UK, Nordic countries, Benelux, rest of Europe) Asia-Pacific (Japan, China, India, Australia, South Korea, Southeast Asia, Rest of Asia-Pacific) Middle East and Africa (Saudi Arabia, UAE, Egypt, South Africa, rest of the Middle East and Africa) Latin America (Brazil, Argentina, rest of Latin America) Rest of the world
Base year	2022
historical year	from 2017 to 2022
Projected year	from 2023 to 2030

Market Dynamics

Chronic diseases such as cancer, heart disease, lung disease, chronic kidney disease (CKD), and rare diseases such as propionic acidemia, methylmalonic acidemia, glycogen disease, phenylketonuria, and metabolic and immune disorders are driving the growth of this market. Caused by an increase in the number of cases. Globocan reports that in December 2020 there were 19 million new cancer cases and 10 million cancer deaths worldwide. In addition, the popularity of mRNA vaccines, the development of personalized cancer treatments, and an extensive portfolio of new products are driving demand for mRNA vaccines and therapeutics, which will help the industry grow over the forecast period.

Operators are likely to invest more in developing advanced and effective drugs and vaccines, which is likely to help the industry grow in the next few years. For example, in April 2021, American mRNA therapeutic developer Arcturus Therapeutics joined forces with Axcelead, Inc. to establish a Japanese company in Chiba Prefecture and is building a manufacturing facility in Minamisoma City, Fukushima Prefecture. In the coming years, these investments are likely to fuel the growth of the industry.

Main segments covered:

Top market players:
Argos Therapeutics, AstraZeneca, Bayer, BioNTech, Boehringer Ingelheim, CRISPR Therapeutics, CureVac, eTheRNA immunotherapy, Ethris, GlaxoSmithKline Vaccines, In-Cell-Art, Intellia Therapeutics, Janssen, Kernal Biologics, MaxCyte, Moderna Therapeutics, Novartis, PhaseRx, Precision NanoSystems , RaNa Therapeutics and others.

Type

• Standardization of an mRNA vaccine for the treatment of cancer
• Customized mRNA vaccine for cancer treatment
• Infectious Disease Treatment MRNA Vaccine
• MRNA vaccine to prevent infections
• Another

By application

By type of treatment

• monoclonal antibody
• Gene therapy
• Cell Therapy
• Other

Regions and countries covered

• North America: (USA, Canada, Mexico, Rest of North America)
• Europe: (Germany, France, Italy, Spain, UK, Nordic countries, Benelux, rest of Europe)
• Asian-Pacific area: (Japan, China, India, Australia, South Korea, Southeast Asia, the rest of the Asia-Pacific region)
• Middle East and Africa: (Saudi Arabia, UAE, Egypt, South Africa, rest of the Middle East and Africa)
• Latin America: (Brazil, Argentina, rest of Latin America)
• Rest of the world

Check out other studies published by Contrive Datum Insights:

• Anal Cancer Therapy Market – IoT management software market size was estimated at $336.81 billion in 2022 and is projected to reach $2282.24 billion by 2030, growing at a CAGR of 27.04% between 2022 and 2030 . North America has the largest market share, with the United States and Canada being the top two countries in the IoT management software market in North America.
• Drug market for dermatophytosis – The global IoT-enabled industrial wearable device market was valued at $1.3 billion in 2022, growing at a CAGR of 23.8% over the analyzed period. Over the forecast time, 42% of market growth will come from North America.
• Exosomal Diagnostics and Therapy Market – The global healthcare Internet of Things (IoT) market is projected to grow from $89.07 billion in 2022 to $446.52 billion in 2030 at a CAGR of 25.9% over 2022-2030. The US had the largest share of income in North America and this is expected to remain true for the next few years.

Edit This Article